Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Beth E. Snitz
Associations between accelerometer‐derived physical activity complexity, cognitive function, and plasma biomarkers of Alzheimer's disease
1 BACKGROUND Dementia is a common neurodegenerative disorder that leads to profound loss of functional independence in older adults.1 Progression to Alzheimer's disease (AD) is hypothesized to begin with a preclinical phase of normal cognition that can precede dementia diagnosis by up to 20 years.2, 3 Recent diagnostic framework highlighted AD as a continuum spans from clinically asymptomatic to severely impaired stages.2 Thus, identifying early changes prior to clinically recognizable...
Voxel-wise hemispheric Amyloid Asymmetry and its association with cerebral metabolism and grey matter density in cognitively normal older adults
GE Healthcare holds a license agreement with the University of Pittsburgh based on the technology described in this manuscript. Dr. Klunk is a co-inventor of PiB and, as such, has a financial interest in this license agreement. GE Healthcare provided no grant support for this study and had no role in the design or interpretation of results or preparation of the manuscript. The other authors declare that they no competing interests.
Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies
DISCUSSION When considering AD biomarker thresholds, it is important to note that the same threshold may not be optimal in all circumstances (11). Indeed, for the centiloid scale, a value of approximately 20 centiloids results in the greatest sensitivity for detecting early Aβ pathology (sensitivity threshold), but a threshold of approximately 50 centiloids better predicts the neuropathologic and clinical diagnosis of AD (specificity threshold) (40).
Biostatistical Estimation of Tau Threshold Hallmarks (BETTH) Algorithm for Human Tau PET Imaging Studies
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas.
Plasma biomarkers identify older adults at risk of Alzheimer's disease and related dementias in a real‐world population‐based cohort
2.4 Statistical analyses Statistical analyses were performed using R 4.1.3.27 We first compared the demographics for participants whose plasma samples were available versus not available. We then examined descriptive statistics of biomarkers and baseline demographics overall and by CDR group or a binary CDR variable (CDR = 0 normal vs. CDR ≥0.5, MCI/dementia).
Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old
Predicting resistance to amyloid-beta deposition and cognitive resilience in the oldest-old Beth E. Snitz, Yuefang Chang, Dana L Tudorascu, Oscar L. Lopez, Brian J. Lopresti, Steven T DeKosky, Michelle C. Carlson, Ann D. Cohen, M. Ilyas Kamboh, Howard J. Aizenstein, William E. Klunk, Lewis H. Kuller Neurology Jul 2020, 10.1212/WNL.0000000000010239; DOI: 10.1212/WNL.0000000000010239
Blood amyloid levels and risk of dementia in the Ginkgo Evaluation of Memory Study (GEMS): A longitudinal analysis
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 GEMS participants with and without plasma Aβ measures stratified by the presence of the APOE-4 allele. Fig. 2 Kaplan–Meier survival curves for incident dementia by Aβ1-42 quartiles in CN and MCI participants. Abbreviations: CN, cognitively normal; MCI, mild cognitive impairment.
Mild Cognitive Impairment that Does Not Progress to Dementia: A Population‐Based Study
Background/Objective In population studies, most individuals with mild cognitive impairment (MCI) do not progress to dementia in the near term, but rather remain stable MCI or revert to normal cognition. Here, we characterized MCI subgroups with different outcomes over 5 years. Setting/Participants A population‐based cohort (N=1603).
Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting
Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: A prospective study in eight cohorts
Amyloid β Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia | Dementia and Cognitive Impairment | JAMA Neurology | JAMA Network
[Skip to Content Landing] Figure 1. Timing of Neuroimaging Relative to Neuropsychological Assessments Participants were evaluated longitudinally from 2000 to 2016. Annual cognitive testing was performed with the exception of a 3- to 4-year gap from 2000 to 2004. Classification of biomarker status was based on Pittsburgh Compound B positron emission tomography and magnetic resonance imaging performed in 2009. Figure 2.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Beth E.
Contact Beth E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack